3
Announcements
Trials
Browse
Landscape
Status
Unknown
2
Terminated
2
Recruiting
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Gynecologic
7
Thoracic
5
NET
4
Endocrine
4
Other solid neoplasm
2
Other hematologic neoplasm
2
Genitourinary
2
Classical hematology
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Docetaxel
205
Prednisone
151
enzalutamide
128
Gemcitabine
122
Radiotherapy
116
Sunitinib
112
Cisplatin
102
Leuprolide
98
pembrolizumab
95
Abiraterone Acetate
94
bicalutamide
87
Nivolumab
85
Goserelin
83
Sorafenib
80
Paclitaxel
79
Carboplatin
77
Everolimus
72
Bevacizumab
71
Magnetic Resonance Spectroscopy
65
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
61
pazopanib
56
radium Ra 223 dichloride
50
Ipilimumab
49
Zoledronic Acid
47
Radiosurgery
43
Cyclophosphamide
43
Filgrastim
42
abiraterone
41
gallium 68 PSMA-11
40
Surveys and Questionnaires
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Data Collection
×
Genitourinary
×
Clear all
NCT03516110
2026-01-23
PRISME
Ipsen
Completed
831 enrolled
NCT03419572
2022-08-15
CASSIOPE
Ipsen
Completed
689 enrolled